Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220258 · ClinicalTrials.gov registry record · Phase 2
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01220258 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 29 participants.
The verdict
NCT01220258, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. Another objective is to determine in subjects with blepharoconjunctivitis the effect of azithromycin ophthalmic solution, 1 % on markers of inflammation of lid margins and conjunctivae and on signs and symptoms of blepharoconjunctivitis.
Interventions
- DRUG Azithromycin ophthalmic solution, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220258
The ClinicalTrials.gov registry entry for NCT01220258 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azithromycin ophthalmic solution, 1% is the first listed.
NCT01220258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220258 about?
NCT01220258 is a clinical study titled "A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)". One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. Another objective is to determine in subjects with blepharoconjunctivitis the effect of azithromycin ophth...
What is the current status of trial NCT01220258?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01220258?
The interventions under investigation include: Azithromycin ophthalmic solution, 1% (DRUG).
Who is sponsoring clinical trial NCT01220258?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.